18 Jul 2018
Posted in Press Release
Personalized medication is becoming an increasing possibility for patients, due to the use of newly developed algorithms
A long sought after objective of healthcare is to ensure that each patient receives tailored treatment for their medical situation; and now, with the use of big data and newly developed algorithms this is starting to look like a genuine possibility for patients, says GlobalData, a leading data and analytics company.
A study conducted at the McLean Hospital in Massachusetts used a specially developed algorithm to identify which patients may respond best to antidepressants, before they begin treatment. The study showed that roughly a third of patients would gain some therapeutic benefit from receiving an antidepressant, with those mostly likely to benefit being older individuals, who are characterised as suffering from more severe depression and negative emotionality, who also demonstrate better cognitive control on computerised tasks.
According to GlobalData’s report: ‘PharmaPoint: Major Depressive Disorder’ there are several different classes of drugs that are prescribed to patients suffering from depression, however, many of these have poor efficacy or safety profiles which leads to later complications and discontinuation of medication.
Rahael Maladwala, Neurology Analyst at GlobalData, comments: “It is estimated that one in three patients do not respond well to the first anti-depressant they are prescribed, and this can lead to difficulties in the future which require medical attention. This puts extra strain on national health services that are already under the pressure of a growing, and aging, population.
“Studies are like this are just the beginning, as technology improves the hope is that physicians will not just be able to tell whether a patient is suited to pharmacological treatment or not, but which specific medication a patient is likely get the highest therapeutic benefit from.
“Personalized medication is inching closer and closer to becoming a reality and could potentially be commonplace for patients in the next twenty years, not just for depression and neurology but across all therapy areas. This in turn means that patients suffer from fewer complications, treatment failures, or adverse events and receive a higher quality of care and reduce the burden on healthcare providers.”